BRIACELL THERAPEUTICS CORP. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
BRIACELL THERAPEUTICS CORP. (BCTX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$15.01 million for the 6-month period ending 2024-01-31, per its 10-Q filed 2024-03-18.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2024-03-18
- BRIACELL THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-10-31 was -$7.61M.
- BRIACELL THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-10-31 was -$3.59M.
- BRIACELL THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-10-31 was -$1.78M.
- BRIACELL THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$19.79M.
- BRIACELL THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$16.23M, a 128.35% decline from fiscal 2021.
- BRIACELL THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $57.25M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2024-01-31 | -$15.01M 10-Q · filed 2024-03-18 | |||
| 2023-10-31 | -$7.61M 10-Q · filed 2023-12-14 | |||
| 2023-07-31 | -$19.79M 10-K · filed 2023-10-25 | |||
| 2023-04-30 | -$12.87M 10-Q · filed 2023-06-14 | |||
| 2023-01-31 | -$7.54M 10-Q · filed 2024-03-18 | |||
| 2022-10-31 | -$3.59M 10-Q · filed 2023-12-14 | |||
| 2022-07-31 | -$16.23M 10-K · filed 2023-10-25 | |||
| 2022-04-30 | -$12.74M 10-Q · filed 2023-06-14 | |||
| 2022-01-31 | -$9.29M 10-Q · filed 2023-03-16 | |||
| 2021-10-31 | -$1.78M 10-Q · filed 2022-12-14 | |||
| 2021-07-31 | $57.25M 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |